Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
| Current Price | ₹1,986.65 |
|---|---|
| Market Cap | ₹15,101 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 23.6 |
| Return on Equity | 19.94% |
| 52-Week Range | ₹1,500.30 – ₹2,395.00 |
| Beta (1Y) | 0.65 |
| Dividend Yield | 0.40% |
1. Pharmaceutical Formulations-100%
Caplin Point Laboratories Ltdte is trading at ₹1,986.65, with a market capitalisation of ₹15,101 Cr.
Caplin Point Laboratories Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Caplin Point Laboratories Ltdte has a P/E of 23.6 and a return on equity of 19.94%.